Pfizer’s $43B Seagen acquisition doubles early-stage oncology clinical pipeline

Pfizer Inc. is set to acquire Seagen Inc. for $229 in cash per Seagen share for a total enterprise value of $43 billion.

(March 15, 2023) | By JIM CORNALL.

Seagen is a global biotechnology company that discovers, develops, and commercializes cancer medicines. The boards of directors of both companies have unanimously approved the transaction.

“Pfizer is deploying its financial resources to advance the battle against cancer, a leading cause of death worldwide with a significant impact on public health,” said Albert Bourla, Pfizer chairman and chief executive officer.